Elixir Medical has received CE mark approval for its Desyne BD Novolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
The Elixir Desyne BD Novolimus Eluting Coronary Stent System was evaluated in the EXCELLA BD randomised clinical trial as compared to the control Endeavor Zotarolimus Eluting Coronary Stent System (Medtronic). The study enrolled patients in Europe and Brazil.
“The CE mark approval validates the impressive clinical results demonstrated with this stent system, including excellent efficacy and no cases of stent thrombosis through the one-year endpoint,” said Alexandre Abizaid, Instituto Dante Pazzanese de Cardiologia in Sao Paulo, Brazil, co-principal investigator for the EXCELLA BD clinical trial. “The combined attributes of lowest polymer load, lowest drug dose, and thin stent struts provides physicians with a state-of-the-art workhorse product that raises the bar for treating patients with coronary artery disease.”
The Elixir Desyne BD stent uses a proprietary technology to enable an ultrathin (< 3 microns) polymer coating without the need for an underlying primer layer. The biodegradable, polylactide-based polymer enables the sustained release of Elixir’s novel therapeutic compound, Novolimus, to the coronary vessel wall and degrades within 6-9 months, leaving behind the cobalt chromium alloy metal stent surface to achieve excellent clinical outcomes.
At six months, the Elixir Desyne BD stent demonstrated not only non-inferiority (p<0.001) but also superiority (p<0.001) over the Endeavor stent for the primary endpoint of in-stent late lumen loss (0.12±0.17 vs. 0.67±0.47, p<0.001).
Similarly, there was a statistical difference in favour of Desyne BD for the secondary end point of binary restenosis (0% vs. 7.9%, p=0.003). In a subset of patients who underwent intravascular ultrasound (IVUS) imaging, the findings mirrored the angiographic results demonstrating a statistically significant reduction in percent neointimal obstruction for the Desyne BD stent versus the Endeavor stent (3.6 ±4.2% vs. 20.7±14.2, p<0.001). Clinical events measured using the device-oriented composite endpoint (DOCE) were low for both Desyne BD and Endeavor (2.7% vs. 3.2%), with Desyne BD sustaining its excellent performance at 12 month follow-up.